
What We’re Reading: CDC Warns About COVID-19 Delta Variant; Regeneron Antibody Results; STD Rates Soar
The CDC classifies the COVID-19 Delta variant a “variant of concern”; results from Regeneron Pharmaceuticals show positive survival benefits in antibody-naïve patients hospitalized because of COVID-19; sexually transmitted diseases (STDs) reach new record levels in the United States.
Delta Variant a “Variant of Concern,” CDC Says
Due to its rapid spread and ability to elude certain antibody treatments, yesterday the CDC deemed the COVID-19 Delta variant a “variant of concern,” reports
Regeneron’s REGEN-COV Shown to Reduce Mortality Risk
REGEN-COV, Regeneron Pharmaceuticals’ antibody treatment against COVID-19 currently being tested in a UK clinical trial, has been shown to reduce mortality risk by 20% among patients hospitalized because of COVID-19, reports
Alarming STDs Levels Seen in the United States
In 2019, the latest year for which CDC data on sexually transmitted diseases (STDs) are available, cases of chlamydia, gonorrhea, and syphilis totaled more than 2.5 million, signifying new record highs for the sixth year in a row, reports
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.